Ambrisentan: A guide to its use in pulmonary arterial hypertension classified as WHO functional class II or III

被引：0
|
作者：
Behr J. [1 ]
Lyseng-Williamson K.A. [2 ]
机构：
[1] Division of Pulmonary Diseases, Department of Internal Medicine i, University of Munich, Munich
[2] Adis, A Wolters Kluwer Business, Auckland
来源：
Drugs & Therapy Perspectives | 2011年 / 27卷 / 1期
关键词：
Ambrisentan; therapeutic use; Endothelin-receptor-antagonists; Pulmonary-hypertension; treatment; Treatment-algorithms;
D O I：
10.2165/11205380-000000000-00000
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：1 / 8
页数：7
相关论文
共 50 条
  • [21] Clinical efficacy of sildenafil in patients with pulmonary hypertension in functional class II or III
    Otero Gonzalez, Isabel
    Blanco Aparicio, Marina
    Souto Alonso, Ana
    Raposo Sonnenfeld, Ines
    Verea Hernando, Hector
    ARCHIVOS DE BRONCONEUMOLOGIA, 2007, 43 (05): : 272 - 276
  • [22] Functional class and prognosis in advanced pulmonary arterial hypertension
    Lescano, A.
    Ferro, A.
    Barimboim, E.
    Coronel, M. L.
    Garcia Brasca, D.
    Huerta, C.
    Stepffer, C.
    Svetliza, G.
    Lobo Marquez, L.
    Manfredi, C.
    Villar, M.
    Naval, N.
    Diez, M.
    Echazarreta, D.
    Perna, E. R.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 318 - 318
  • [23] Management of Pulmonary Arterial Hypertension Patients with World Health Organization Functional Class II
    Hung, Cheng Chung
    Cheng, Chin-Chang
    Huang, Wei-Chun
    Lin, Kun-Chang
    Kuo, Feng-Yu
    Kuo, Shu-Hung
    Yang, Tse-Hsuan
    Liang, Hsin-Li
    Mar, Guang-Yuan
    ACTA CARDIOLOGICA SINICA, 2020, 36 (06) : 583 - 587
  • [24] Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients
    Simonneau, Gerald
    Galie, Nazzareno
    Jansa, Pavel
    Bohns Meyer, Gisela Martina
    Al-Hiti, Hikmet
    Kusic-Pajic, Andjela
    Lemarie, Jean-Christophe
    Hoeper, Marius M.
    Rubin, Lewis J.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 172 (02) : 332 - 339
  • [25] Prognostic risk factors of disease worsening in patients with functional class II pulmonary arterial hypertension
    Simonneau, Gerald
    Galie, Nazzareno
    Hoeper, Marius M.
    Kusic-Pajic, Andjela
    Lemarie, Jean-Christophe
    Rubin, Lewis J.
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [26] Does Sitaxsentan Therapy Offer Benefit To Functional Class II Patients With Pulmonary Arterial Hypertension
    Langleben, D.
    Delcroix, M.
    Ghofrani, H. A.
    Torbicki, A.
    Burgess, G.
    Morris, M.
    Teal, S.
    Vachiery, J. -L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [27] Correlation of WHO Functional Class and Patient-Reported Outcome Measures in Adults With Pulmonary Arterial Hypertension
    El-Kersh, K.
    Highland, K. B.
    Wilson, M.
    Broderick, M.
    Wu, B.
    Seaman, S.
    Classi, P.
    Dubrock, H. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [28] Bosentan is a cost-effective treatment for united kingdom patients with pulmonary arterial hypertension of WHO class III
    Stevenson, M. D.
    MacDonald, F. C.
    Langley, J.
    Akehurst, R. L.
    VALUE IN HEALTH, 2008, 11 (03) : A197 - A197
  • [29] Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study
    Vachiery, Jean-Luc
    Hoeper, Marius M.
    Peacock, Andrew J.
    Sitbon, Olivier
    Cheli, Martino
    Church, Cohn
    Olsson, Karen M.
    Palazzini, Massimiliano
    Waterhouse, Brian
    Langley, Jonathan
    Galie, Nazzareno
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : 399 - 406
  • [30] SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: IS IT FEASIBLE TO DIAGNOSE AND MAINTAIN PATIENTS IN WORLD HEALTH ORGANIZATION (WHO) FUNCTIONAL CLASS II?
    Dall'Ara, F.
    Zingarelli, S.
    Scarsi, M.
    Tincani, A.
    Airo, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1131 - 1131
12345